HEALTHCARE IT & HEALTHTECH
Strategic acquirers in this market are buying their way into a clinical or revenue workflow they cannot build fast enough. Which workflow you own, how deeply you are embedded in it, and how hard you are to rip out matter more to your valuation than growth rate alone. Most founders present the product. The value is in the position.
Transactions completed firmwide
Aggregate transaction value
Cross-border deals transacted
YOUR BANKER
Gary co-founded Nfluence and leads our Healthcare IT advisory practice. A former technology founder and CEO himself, Gary brings over two decades of high-stakes technology M&A experience to every founder conversation.
Managing Partner & Co-Founder
WHAT WE DO
Whether structuring a sell-side exit, finding strategic co-investors, or arranging growth equity, we position HealthTech companies for maximum market conviction.
We position complex healthcare technology assets to secure top-tier multiples in competitive auctions.
Securing growth capital engineered to scale clinical deployments and enterprise sales.
Deep domain experience across critical healthcare workflow, data, and patient management ecosystems.
Automated billing, claims processing, denial management, prior authorization, and patient financial clearance.
Digital self-scheduling, digital front door, patient intake automation, and clinical communication platforms.
Cloud EHR platforms, specialty practice management, clinical documentation, and ambulatory workflow software.
Care coordination, nursing workflows, clinical decision support, and provider scheduling optimization.
Virtual care platforms, remote patient monitoring (RPM), asynchronous consults, and hybrid care delivery.
E-prescribing, specialty pharmacy workflow, medication adherence, inventory management, and 340B compliance.
Specialized EHR, measurement-based care software, tele-therapy infrastructure, and mental health outcomes tracking.
FHIR API integration, health information exchange (HIE), clinical data pipelines, and payer-provider data sharing.
Where our senior bankers trained before Nfluence.
YOUR OPTIONS
Every banker says they run a competitive process. Here is what actually changes depending on which route you take.
Enough that no single party sets the terms
What the market will actually pay, priced by competition
Four to seven months
Highest, and planned for
Real alternatives, including walking away
Managed deliberately, under NDA and staged disclosure
| Metric | Take the inbound call | Run a limited process | Run a full process |
|---|---|---|---|
| Buyers at the table | One | Two or three | Enough that no single party sets the terms |
| What you learn about the market | One party's view of your value | A partial read | What the market will actually pay, priced by competition |
| Time required | Weeks, mostly reactive | Two to four months | Four to seven months |
| Disruption to the business | Low at first, high if it drags | Moderate | Highest, and planned for |
| Your negotiating position | Whatever they decide to offer | Some leverage on price and terms | Real alternatives, including walking away |
| Confidentiality | Easiest to contain | Manageable | Managed deliberately, under NDA and staged disclosure |
Timeframes are typical ranges for middle-market technology transactions and vary by company, sector, and market conditions.
Acquired by Cvent (Blackstone)
Exclusive financial advisor to the seller
Has been acquired by LEMNIS
Financial advisor on its sale to LEMNIS
Strategic recapitalization
Lead placement agent
Acquired by Visit Group, a portfolio company of PSG
Financial advisor to the seller
Has been acquired by Mode Mobile
Exclusive financial advisor to the seller
Has been acquired by Zucchetti
Exclusive financial advisor to the seller
Growth debt financing from Trinity Capital and Level Equity Financing
Lead placement agent
Has been acquired by Monex Financial Group / Coincheck
Exclusive financial advisor to the seller
Acquired by Aldrich Capital Partners
Exclusive financial advisor to the company
Advised PracticeSuite on acquisition of MicroMD
Exclusive financial advisor to the buyer
Received financing from Heritage Bank of Commerce
Capital raise lead
Carve-out from Henry Schein acquired by PracticeSuite
Exclusive financial advisor to the buyer
Acquired by Level Access, a portfolio company of KKR & JMI Equity
Financial advisor to the seller
Has been acquired by Charlesbank Capital Partners
Exclusive financial advisor to the seller
Has been acquired by Yieldstreet
Exclusive financial advisor to the seller
Follow-on public offering
Financial advisor on follow-on equity offering
Has been acquired by Constellation Software
Exclusive financial advisor to the seller
Advised on strategic acquisition of Rotor Video
Exclusive financial advisor to the buyer
* Select transactions shown. Includes current Nfluence bankers' experience at prior firms. Full track record available upon request.
INSIGHTS
Perspectives on healthcare IT M&A, digital health valuation multiples, and provider-payer consolidation.
How AI documentation and automated coding software are redefining healthcare SaaS multiples and hospital procurement.
Read moreWhy private equity sponsors are paying premium multiples for automated prior-authorization and claims denial management platforms.
Read moreM&A volume in financial services rose 3% while total deal value fell roughly 30%, with top transactions taking the lion's share of liquidity.
Read more
The accelerating shift of private equity and strategic investment into B2B workforce development and technical credentialing.
Read moreTHE MARKET READ
Healthcare IT and digital health transaction value across strategic M&A and buyouts in 2026.
Of enterprise health systems consolidating vendor contracts into unified software suites.
Median ARR multiple for HealthTech platforms demonstrating verifiable ROI in clinical labor reduction.
Healthcare technology trades on entrenchment. A company with modest growth sitting inside a clinical workflow that cannot be replaced is worth more than a faster-growing product that sits alongside one. The work is proving where you sit, to the specific acquirers whose roadmap has a hole in that shape.
For HealthTech companies scaling past $10M in ARR, positioning requires demonstrating low customer churn among enterprise health networks, strong gross margins, and clear defensibility against legacy incumbents. A competitive M&A process creates tension between strategic healthcare conglomerates seeking modern cloud capabilities and well-capitalized private equity platforms executing buy-and-build strategies.
Rock Health, PitchBook Healthcare Report, and Nfluence Partners proprietary healthcare transaction database.
WHERE WE'LL BE
If you are going to Las Vegas, twenty minutes on the floor is worth more than a call in November. Gary keeps a handful of slots open for founders thinking about the next eighteen months.
The Venetian Expo. Las Vegas, Nevada
Gary Moon, Managing Partner & Co-Founder
Not a pitch, and not a booth conversation. Bring the question you would actually want answered before you run a process. What companies like yours traded for this year. Which acquirers are active in your category right now and which have gone quiet. Whether your timing is right or whether you are eighteen months early.
You will get a straight answer, and if we are not the right firm Gary will say so and point you somewhere better.
HLTH brings together thousands of healthcare leaders and investors. Meeting slots fill well in advance of the conference.
Not going to HLTH? Gary is in San Francisco and New York regularly through the fall. Book a call instead.
FAQ
Talk to us. We'll give you two numbers: the conservative one and the outlier. In healthcare, value tracks how deeply you're embedded in a clinical or revenue workflow, not just growth rate. We'll show you what comparable companies sold for this year. The outlier usually comes from a buyer whose roadmap has a gap in exactly your shape. Finding that buyer is the job.
Not yet. If they integrate with you, they already know your usage and your customers. That advantage shows up in their offer. Check your integration and reseller agreements for change-of-control or first-refusal terms, then let us bring in alternatives, including PE platforms building in your category. Gary has been a founder and CEO himself, so he knows what the other side of the table looks like.
Buyers don't need PHI to value you, and we design the process so they don't get it. Diligence runs on de-identified and aggregated data, architecture reviews, and security documentation under NDA. Customer names stay blinded until late stages. A senior banker controls each stage of disclosure personally.
No. Healthcare deals take longer to prepare. HIPAA documentation, SOC 2 or HITRUST, provider and payer contract reviews, and clean revenue recognition all take months. Most founders we take to market, we met a year or two early. That's the window to fix what slows diligence and get known by the buyers most likely to pay.
More than you'd think, and Nfluence can be one of them. Minority growth rounds, structured debt, and partial recaps can all fund the next stage without a sale. Our merchant banking practice also invests directly in mission-aligned digital health companies. The advisory and investment teams operate separately, and we disclose any potential conflict upfront.
Differently, so know which story you're telling. Workflow software embedded in daily clinical operations wins on retention and switching cost. RCM tools win on measurable ROI: claims paid faster, fewer denials, labor saved. If you have both, show each on its own terms.
Diligence never requires PHI disclosure. All technical evaluation is performed on de-identified synthetic datasets and architecture diagrams under strict non-disclosure agreements.
Only if you can't show they're staying and growing. Buyers want multi-year retention, expansion within each system, and renewal history. A few large, expanding systems can be a strength. A few large systems up for renewal mid-process is a risk we'll want to time around.
Yes, for some categories. If any part of your product could be regulated as a medical device, buyers will diligence your regulatory position closely. Clear clearance, or a documented rationale for why clearance isn't needed, protects value. Published outcomes add to it. We frame this with your regulatory counsel before buyers ask.
Directly. If your customers' revenue depends on CMS codes or payer policy, buyers will stress-test what happens when those change. Show how your revenue holds across reimbursement scenarios and how diversified your payer exposure is. Modeling it upfront earns more credit than letting diligence find it.
Start with what the next stage requires. If health system sales cycles and integration demands outpace what you can fund, a strategic partner may get you there faster. If the model is working and you need fuel, a growth round keeps the upside. We don't have a preference. We're paid to help you pick correctly.
.png){kind=logo}
